Why the study?
Does moxonidine reduce glomerulosclerosis and albuminuria in subtotally nephrectomized rats?
Population
Sprague Dawley rats, subtotally nephrectomized (SNX) or sham-operated (control)
Comparison
Moxonidine 1.5 mg/kg body wt per day vs Untreated SNX rats and sham-operated controls
Design
Preclinical
Authors
Loading...
Supports sympathetic inhibition in experimental CKD models; leaves open translation to human trials.
Does moxonidine reduce glomerulosclerosis and albuminuria in subtotally nephrectomized rats?
At subantihypertensive doses, moxonidine ameliorates renal structural and functional damage in subtotally nephrectomized rats, possibly through central inhibition of efferent sympathetic nerve traffic.
Amann et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: